SPP1 and metabolic dysfunction-associated steatotic liver disease: To the best of our knowledge, no longitudinal studies have examined serum OPN concentrations throughout the natural history of MASLD, nor have any assessed serum OPN concentrations in patients with MASLD across multiple consecutive visits during follow-up, which would be needed to elucidate the role of OPN in the development and progression of this liver disease.